Go back

Evidence-base prioritised by medicines agency head

Guido Rasi, the recently appointed executive director of the European Medicines Agency, has said he wants to improve the use of evidence in regulation during his five-year term.

Outlining his five-year vision, Rasi said the agency will focus on R&D for medicines that address public health needs and will make the best use of all available evidence to study medicines’ safety and efficacy. He also wants to increase the involvement of patients in its work, commit to transparency, and become the global reference authority for the regulation of medicines, he said.

Rasi opened the press conference on 10 December by saying that more changes in medicines development were taking place now than in his 35 years of working in public health. These included a “vast” evolution in the understanding of the human body, increased globalisation of medicines development and manufacturing, and increased pressure on healthcare systems, he said. 

This article is only available to Research Professional News subscribers or Pivot-RP users.

If you are a Research Professional News subscriber you can log in and view the article via this link

Pivot-RP users can log in and view the article via this link.